{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:03:06Z","timestamp":1780736586979,"version":"3.54.1"},"update-to":[{"DOI":"10.1371\/journal.ppat.1009383","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000}}],"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Commonwealth of Pennsylvania, Department of Community and Economic Development"},{"name":"Bharat Biotech, India"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.<\/jats:p>","DOI":"10.1371\/journal.ppat.1009383","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T16:34:43Z","timestamp":1616690083000},"page":"e1009383","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-7700","authenticated-orcid":true,"given":"Drishya","family":"Kurup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine C.","family":"Malherbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-7281","authenticated-orcid":true,"given":"Christoph","family":"Wirblich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7825-4233","authenticated-orcid":true,"given":"Rachael","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-9154","authenticated-orcid":true,"given":"Adam J.","family":"Ronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Zabihi Diba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-4824","authenticated-orcid":true,"given":"Alexander","family":"Bukreyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-9405","authenticated-orcid":true,"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"ppat.1009383.ref001","unstructured":"World Health Organization."},{"key":"ppat.1009383.ref002","unstructured":"Centers for Disease Control and Prevention."},{"key":"ppat.1009383.ref003","doi-asserted-by":"crossref","unstructured":"Kaiser J. Temperature concerns could slow the rollout of new coronavirus vaccines. https:\/\/www.sciencemag.org\/news\/2020\/11\/temperature-concerns-could-slow-rollout-new-coronavirus-vaccines.","DOI":"10.1126\/science.abf7422"},{"issue":"9\u201310","key":"ppat.1009383.ref004","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: principles, progress and prospects","volume":"18","author":"WW Leitner","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"ppat.1009383.ref005","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1038\/s41598-020-61103-1","article-title":"Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus","volume":"10","author":"H Garg","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"ppat.1009383.ref006","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"A Roldao","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"ppat.1009383.ref007","unstructured":"GAVI. https:\/\/www.gavi.org\/vaccineswork\/what-are-viral-vector-based-vaccines-and-how-could-they-be-used-against-covid-19."},{"issue":"3","key":"ppat.1009383.ref008","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines.","volume":"2","author":"T Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"ppat.1009383.ref009","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and Multipathogen Viral Vector Vaccines","volume":"24","author":"KB Lauer","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"49","key":"ppat.1009383.ref010","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.vaccine.2013.09.038","article-title":"Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment","volume":"31","author":"AB Papaneri","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"ppat.1009383.ref011","doi-asserted-by":"crossref","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"JE Blaney","year":"2013","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1009383.ref012","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/13550280590900436","article-title":"The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines","volume":"11","author":"MJ Schnell","year":"2005","journal-title":"J Neurovirol"},{"issue":"1","key":"ppat.1009383.ref013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2260","article-title":"The cell biology of rabies virus: using stealth to reach the brain","volume":"8","author":"MJ Schnell","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"ppat.1009383.ref014","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.01870-09","article-title":"Characterization of a single-cycle rabies virus-based vaccine vector","volume":"84","author":"EA Gomme","year":"2010","journal-title":"Journal of virology"},{"issue":"6","key":"ppat.1009383.ref015","doi-asserted-by":"crossref","first-page":"e67123","DOI":"10.1371\/journal.pone.0067123","article-title":"Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses","volume":"8","author":"TM Lawrence","year":"2013","journal-title":"PloS one"},{"issue":"2","key":"ppat.1009383.ref016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.virol.2005.09.004","article-title":"Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2","volume":"344","author":"JP McGettigan","year":"2006","journal-title":"Virology"},{"key":"ppat.1009383.ref017","doi-asserted-by":"crossref","first-page":"43339","DOI":"10.1038\/srep43339","article-title":"The Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees?","volume":"7","author":"PD Walsh","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"ppat.1009383.ref018","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1086\/512243","article-title":"Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease","volume":"195","author":"PM McKenna","year":"2007","journal-title":"The Journal of infectious diseases"},{"issue":"9","key":"ppat.1009383.ref019","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiz332","article-title":"Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge","volume":"220","author":"D Kurup","year":"2019","journal-title":"The Journal of infectious diseases"},{"issue":"suppl 3","key":"ppat.1009383.ref020","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models","volume":"214","author":"RF Johnson","year":"2016","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ppat.1009383.ref021","doi-asserted-by":"crossref","first-page":"657","DOI":"10.20506\/rst.37.2.2831","article-title":"New developments in rabies vaccination.","volume":"37","author":"CR Fisher","year":"2018","journal-title":"Rev Sci Tech"},{"issue":"1","key":"ppat.1009383.ref022","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"T Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"ppat.1009383.ref023","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02040-16","article-title":"One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus","volume":"91","author":"C Wirblich","year":"2017","journal-title":"Journal of virology"},{"key":"ppat.1009383.ref024","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-019-0109-5","article-title":"Rabies-based vaccine induces potent immune responses against Nipah virus","volume":"4","author":"R Keshwara","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"6","key":"ppat.1009383.ref025","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01865-18","article-title":"A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model","volume":"93","author":"R Keshwara","year":"2019","journal-title":"Journal of virology"},{"key":"ppat.1009383.ref026","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1038\/mtm.2014.46","article-title":"Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo","volume":"1","author":"AW Hudacek","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"ppat.1009383.ref027","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"D Kurup","year":"2015","journal-title":"Journal of virology"},{"key":"ppat.1009383.ref028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.coviro.2020.09.003","article-title":"Rhabdoviruses as vectors for vaccines and therapeutics","volume":"44","author":"G Scher","year":"2020","journal-title":"Curr Opin Virol"},{"issue":"4","key":"ppat.1009383.ref029","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: conquering new frontiers","volume":"16","author":"CR Fisher","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"ppat.1009383.ref030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-020-00248-6","article-title":"Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2","volume":"5","author":"D Kurup","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"6","key":"ppat.1009383.ref031","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3201\/eid2606.200516","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States","volume":"26","author":"J Harcourt","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"7818","key":"ppat.1009383.ref032","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"SF Sia","year":"2020","journal-title":"Nature"},{"key":"ppat.1009383.ref033","doi-asserted-by":"crossref","first-page":"m3862","DOI":"10.1136\/bmj.m3862","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"371","author":"M Cevik","year":"2020","journal-title":"BMJ."},{"key":"ppat.1009383.ref034","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"ppat.1009383.ref035","unstructured":"Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine. NIAID Office of Communications. https:\/\/www.nih.gov\/news-events\/news-releases\/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine [Internet]. November 16, 2020."},{"key":"ppat.1009383.ref036","unstructured":"U.S. Food and Drug Administration."},{"issue":"7821","key":"ppat.1009383.ref037","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"L Liu","year":"2020","journal-title":"Nature"},{"issue":"11","key":"ppat.1009383.ref038","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"LH Tostanoski","year":"2020","journal-title":"Nat Med"},{"key":"ppat.1009383.ref039","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","author":"L Sanchez-Felipe","year":"2020","journal-title":"Nature"},{"key":"ppat.1009383.ref040","article-title":"Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters","author":"L. Rebecca","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"ppat.1009383.ref041","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Y Dong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"ppat.1009383.ref042","article-title":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia","author":"VA Simonovich","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"ppat.1009383.ref043","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study","volume":"26","author":"STH Liu","year":"2020","journal-title":"Nat Med"},{"issue":"7821","key":"ppat.1009383.ref044","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"DF Robbiani","year":"2020","journal-title":"Nature"},{"issue":"6504","key":"ppat.1009383.ref045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"X Chi","year":"2020","journal-title":"Science"},{"issue":"1","key":"ppat.1009383.ref046","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41467-019-10897-4","article-title":"Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein","volume":"10","author":"H Zhou","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"ppat.1009383.ref047","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1038\/s41379-020-00661-1","article-title":"COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City","volume":"33","author":"AC Borczuk","year":"2020","journal-title":"Mod Pathol."},{"issue":"1","key":"ppat.1009383.ref048","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chest.2020.09.259","article-title":"Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review","volume":"159","author":"LP Hariri","year":"2021","journal-title":"Chest"},{"issue":"28","key":"ppat.1009383.ref049","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"M Imai","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"ppat.1009383.ref050","doi-asserted-by":"crossref","DOI":"10.3390\/v11121118","article-title":"Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines","volume":"11","author":"C Chen","year":"2019","journal-title":"Viruses"},{"issue":"13","key":"ppat.1009383.ref051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134782","article-title":"Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications","volume":"21","author":"A Allegra","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ppat.1009383.ref052","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1002\/cpmc.100","article-title":"SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup","volume":"57","author":"D Stadlbauer","year":"2020","journal-title":"Curr Protoc Microbiol."},{"issue":"5","key":"ppat.1009383.ref053","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","article-title":"An Infectious cDNA Clone of SARS-CoV-2","volume":"27","author":"X Xie","year":"2020","journal-title":"Cell Host Microbe."}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1009383","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1009383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T08:15:44Z","timestamp":1671696944000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1009383"}},"subtitle":[],"editor":[{"given":"Benhur","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1009383","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.19.427373","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}